NCT04153474

Brief Summary

Regarding to the distribution of nephrostomy tube (NT) size usage by country. There was a clear distinction between countries that used solely the small bore (SB) NT (Chile and Australia) and those that used solely the large bore (LB) NT (Czech Republic and Japan). There is also a trend toward SB NT in North America (\~75% in USA and Canada) and toward LB NT in South America (\~80% in Argentina and Mexico). In Europe the trend is equal (\~50% in Germany, France, Greece and UK). Based on previous data and in view of conflicting data about postoperative complication including extravasation, bleeding and hemoglobin change and pain between previous studies, we will conduct this randomised trial comparing SB and LB NT following PNL. Our aim to evaluate the safety of small versus large bore NT reporting complications using the Clavien-Dindo system with categorisation of PNL-specific complications

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
220

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2019

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

November 4, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 6, 2019

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2020

Completed
Last Updated

November 6, 2019

Status Verified

October 1, 2019

Enrollment Period

9 months

First QC Date

November 4, 2019

Last Update Submit

November 4, 2019

Conditions

Keywords

Percutaneous nephrolithotomy (PNL)Nephrostomy tube (NT)PainPatient satisfaction

Outcome Measures

Primary Outcomes (1)

  • Rate of hemoglobin reduction difference between groups

    measured in gram/liter

    8 months

Secondary Outcomes (3)

  • postoperative pain score

    8 months

  • postoperative patient satisfaction

    8 months

  • overall postoperative complication

    8 months

Study Arms (2)

large-bore nephrostomy tube (LBNT)

ACTIVE COMPARATOR

large-bore 22 french nephrostomy tube (LBNT)

Procedure: large-bore nephrostomy tube (LBNT)

small-bore nephrostomy tube (SBNT)

ACTIVE COMPARATOR

small-bore 14 french nephrostomy tube (SBNT)

Procedure: small-bore nephrostomy tube (SBNT)

Interventions

large-bore 22 french nephrostomy tube (LBNT)

Also known as: LBNT
large-bore nephrostomy tube (LBNT)

small-bore 14 french nephrostomy tube (SBNT)

Also known as: SBNT
small-bore nephrostomy tube (SBNT)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Staghorn calculi
  • Renal pelvis stones =\>2 cm
  • Lower pole stones= \>1.5 cm
  • upper ureteral calculi =\>1.5 cm
  • SWL-resistant stones

You may not qualify if:

  • Age \<18 years or Pregnancy
  • Tubeless PNL
  • Need for 3 percutaneous tracts intraoperative
  • Morbid obesity (BMI \>40)
  • Refuse to complete study requirements
  • Tumour in the presumptive access tract area or Potential malignant kidney tumour

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Urology and Nephrology Center

Al Mansurah, Aldakahlia, 35516, Egypt

Location

MeSH Terms

Conditions

UrolithiasisPainPatient Satisfaction

Condition Hierarchy (Ancestors)

Urologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsTreatment Adherence and ComplianceHealth BehaviorBehavior

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 4, 2019

First Posted

November 6, 2019

Study Start

May 1, 2019

Primary Completion

February 1, 2020

Study Completion

February 1, 2020

Last Updated

November 6, 2019

Record last verified: 2019-10

Data Sharing

IPD Sharing
Will not share

Locations